Xenomics was out with a follow up to news story to their news earlier this week on getting clinical trials rolling.
I continue to be fascinated by the potential for commercial applications for the use of Transrenal DNA. It’s amazing to me that no one ever figured out that DNA did pass through the kidneys unfiltered. DNA can be used to identify a myriad of potential maladies.
Clearly, the most immediate potentially profitable application for Transrenal DNA is as a replacement test for Amniocentisis- What pregnant women would not prefer a urine test over the insertion of an eight inch needle into her abdomen?
XNOM announced earlier this week it had arranged to begin clinical trials at Long Island’s LIJ Health services. A follow up annoucement came a day later as the company announced it would also be conducting trials at Eastern Virginia Medical School.
XNOM is now on a fast track to get its first commercial product through the FDA process. It won’t be a five year process- it’s a non-invasive urine test. They just have to show it works.
As clinical data becomes available on test results, look for interest to start picking up in this stock. In the interim, if you are a long term investor and want to own a piece of a company with a revolutionary approach to DNA testing, this one has great potential.
As always, comments and questions are welcome.
My brother is a research biophysicist at a major Texas med school. I asked him about this and his comments indicated that this a very viable technology, very profitable once it is used at least once with good results, and the same technology can be used in hundreds of other applications. However, these take years, sometimes as long as a decade to come to fruition, so betting on this is a definite long-term focus. I’d say at least 3 years to get the 10-bagger. But then 1000% profit over 3 years is indeed worth the wait! IMHO
Editor: The management at the company believes it will take two years to get through the FDA Approval process. In the interim, the stock could begin to get noticed as they release clinical data during the trials. Glad to hear someone else sees the same potential I do. Diagnostics is huge- Abbott does $20 billion in diagnostics.
Long term the potential of the technology is great, but in the short term owning this stock is like dancing in a mine field. My year-end request for OTC Journal was better coverage of the private placement situation and outstanding shares for each of the stocks you follow. This one is a prime example. You really should put out an edition explaining this stock’s outstanding shares and its risks rather than chance yet another embarassing meltdown when your readers get caught by surprise by an overwhelming number of new shares hitting the market. July 2 is only 46 days away.
Editor: There is the technical and the fundamental side of every situation. I have often seen stocks trade extremely well in the face of potential excess supply, and some do very poorly when excess supply is out there. I have been cautioning this stock is for long term investors only, which is the same thing. Market cap vs corporate performance is far more important. For example, look at HDY- 6 million shares are eligible to be free trading on that one at $.75 since Feb 1, and nearly none has been filed for sale. I don’t believe it makes sense to be paralyzed by the fear of excess supply when things make sense. Neither you nor I can possibly know the intentions of those shareholders.
what do they have to do with used auto parts i am suspicious of these guys
Editor: I’m not sure I know what you are talking about, but this stock is sure doing well.